2022
DOI: 10.1111/vde.13128
|View full text |Cite
|
Sign up to set email alerts
|

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases

Abstract: Background The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE. Objectives To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. Animals Seven dogs were diagnose… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
14
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 13 publications
(20 citation statements)
references
References 15 publications
1
14
0
Order By: Relevance
“…It has the potential to inhibit the activation of receptors for several cytokines involved in autoimmunity, such as IL‐2, IL‐15, interferon (IFN)‐α and IFN‐γ. At higher doses 11 (equivalent to approximately 3–4 mg/kg), oclacitinib has immunomodulatory effects on T‐cell proliferation in addition to cytokines. It has been reported to be effective in a number of immune‐mediated dermatoses, such as hyperkeratotic erythema multiforme, cutaneous lupus erythematosus and pemphigus vulgaris 7–9 …”
Section: Discussionmentioning
confidence: 99%
“…It has the potential to inhibit the activation of receptors for several cytokines involved in autoimmunity, such as IL‐2, IL‐15, interferon (IFN)‐α and IFN‐γ. At higher doses 11 (equivalent to approximately 3–4 mg/kg), oclacitinib has immunomodulatory effects on T‐cell proliferation in addition to cytokines. It has been reported to be effective in a number of immune‐mediated dermatoses, such as hyperkeratotic erythema multiforme, cutaneous lupus erythematosus and pemphigus vulgaris 7–9 …”
Section: Discussionmentioning
confidence: 99%
“…Individual case reports and small case series have documented oclacitinib to be effective for several nonallergic (and immune-mediated) diseases at doses ranging from 0.2-1.8 mg/kg once daily to 0.5-0.9 mg/kg twice daily. [5][6][7][8][9] This suggests a highly individualised response rate for nonallergic diseases. Although the exact pathogenesis of the sebaceous gland destruction in ISA remains unknown, current theories attribute it to a T-cell-mediated immunological targeting of the glands.…”
Section: Discussionmentioning
confidence: 99%
“…Owing to the potential for oclacitinib to inhibit the activation of receptors for some cytokines involved in autoimmunity, such as interleukin (IL)-2 and IL-15 and interferon (IFN)-α and IFN-γ, there are now several published case reports on the usefulness of oclacitinib for the treatment of canine autoimmune subepidermal blistering dermatosis, 5 generalised ischaemic vasculopathies, 6 pemphigus vulgaris, 7 hyperkeratotic erythema multiforme 8 and chronic cutaneous lupus erythematosus variants. 9 The present work describes the use of oclacitinib and low-dose prednisolone for the treatment of a case of canine ISA.…”
Section: Introductionmentioning
confidence: 99%
“…22,23 Several off-label reports have deemed OC successful for the management of autoimmune diseases such as erythema multiforme, cutaneous lupus erythematosus and pemphigus vulgaris. [24][25][26] The offlabel doses of OC used in these case reports ranged…”
Section: Introductionmentioning
confidence: 99%
“…Oclacitinib has immunomodulatory activity with a high affinity towards JAK1 and JAK2 and inhibits interleukins (IL)‐2, IL‐4, IL‐6, IL‐13 and IL‐31 22,23 . Several off‐label reports have deemed OC successful for the management of autoimmune diseases such as erythema multiforme, cutaneous lupus erythematosus and pemphigus vulgaris 24–26 . The off‐label doses of OC used in these case reports ranged from 0.6 to 1.0 mg/kg twice daily.…”
Section: Introductionmentioning
confidence: 99%